Expert Considerations Guide

This resource has been developed in collaboration with 3 healthcare professionals working in the field of bladder cancer to support the integration of the KEYTRUDA® (pembrolizumab) + enfortumab vedotin▼ (EV) regimen into NHS pathways. This Expert Considerations Guide should be used in conjunction with published guidance and recommendations, where available.

Prescribing Information [External link]

KEYTRUDA, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.¹

Please refer to the Summary of Product Characteristics and Risk Minimisation Materials for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

Reference

1. KEYTRUDA Summary of Product Characteristics.